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Is donor or recipient ACE-genotype associated with long-term graft
survival after renal transplantation (RT)? J. Broekroelofs, CA. Stegeman,
G.J. Navis, H. Scheffer, AM. Tegzess, D. de Zeeuw, FE. de Jong, University
Hospital Groningen, The Netherlands. In chronic renal failure, renal
function loss is more rapid in patients with the DD ACE-genotype. As
long-term renal function loss is common after RT, we investigated
whether donor or recipient ACE-genotype affects long-term graft survival.
ACE-genotype was determined by PCR in stored lymphocytes from 318
recipient/donor pairs transplanted between 1987 and 1993, with at least I
year of graft survival. Mean follow-up was 52 months. Graft survival,
defined as need for renal replacement, was calculated by the Kaplan-
Meyer life-table method from I to 5 years. Patients dying with a
functioning graft were treated as lost to follow-up. Influence of other
factors possibly related to graft survival beyond 12 months [acute rejec-
tions (AR), number of HLA-DR mismatches, preservation time, primary
non-function, sex mismatch and donor age) were tested with a test for
trend. Results: pure graft survival (1—5 yr; %).
Recipient
genotype N 3 year 4 year 5 year
II 80 95 95 93
ID 164 98 94 90
DD 74 90 87 87
Interestingly, donor genotype was not significantly associated with graft
survival. Also between the 3 recipient ACE-genotypes graft survival was
not significantly different (log rank test). Relative risk (RR) for graft
failure in DD recipients is 1.82 (95% Cl 0.66 to 5.01) versus II recipients.
Of the other factors only AR was independently associated with graft
survival. Corrected for AR, the RR for DD-versus Il-recipients was 1.86
(95% CI 0.62 to 5.54). When patients dying with functioning graft were
included as graft failure, 5-year graft failure in DD recipients was higher
than in II recipients RR 1.92 (95% Cl 0.91 to 4.02). In conclusion, neither
donor nor recipient ACE-genotype significantly affected pure graft sur-
vival.
The polycystic kidney disease 1 gene: Mutation detection and immuno-
histochemical analysis of the gene product polycystine. D.J.M. Peters,
J. Roelfsema, L. Spntit, E. tIe Heer, iA. Bruijn, M.H. Breuning, Department
of human Genetics and Department of Patholorj, Leiden University, The
Netherlands. Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most frequent inherited diseases. The PKDI gene, mutated in
approximately 85% of ADPKD patients, encodes a novel protein with an
unknown function, named polycystine. The structure of polycystine sug-
gests a primary defect in cell-cell or cell-matrix interactions. Until now few
mutations have been described. Mutation detection for PKD1 is signifi-
cantly hampered since a large part of the gene is reiterated several times
at another locus on chromosome 16. We reduced the problems posed by
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the repeated area by using the Protein Truncation Test (PTT), a straight-
forward method which detects translation terminating mutations. With the
PIT we have found 8 mutations in the repeated region of the PKD1 gene.
To get further insight in the function of polycystine, we raised polyclonal
antibodies against synthetic peptides and fusion proteins corresponding to
the sequence of polycystine. Two of the antibodies were capable of
immunoprecipitating in vitro generated fragments of polycystine. Immu-
nohistochemical analysis showed in normal adult and embryonic kidney
tissues expression in the epithelium of all tubular structures and in the
glomerular parietal and visceral epithelium (podocytes), although the
podocytes were mainly recognized on cryo-sections and not on paraffin
sections. In the cyst lining epithelium of PKD1 patients an increased
staining intensity was observed. Interestingly, in kidney tissue of a patient
with a stop mutation in exon 15, strong staining was observed with
antibodies against epitopes within exon 24 and exon 46, suggesting an
up-regulation of the wild-type protein. These data suggest localization of
polycystine in glomerular and tubular (cystic) epithelia. Aberrant expres-
sion of polycystine could he responsible for the morphological alterations
observed in cystogenesis.
Infusion of low dose .&NF in normoalbuminuric type I diabetic patients:
uncovering susceptibility to (incipient) nephropathy? G. Vervoort, JF.M.
Wetzels, J.A. Lutterman, P. Smits and J.H.M. Berden, Departments of
Medicine and Pharmacolo,, University Hospital Nijmegen, The Nether-
lands. About 30% of type 1 diabetic patients will develop diabetic
nephropathy (DNP). A hemodynamic basis for DNP is suggested by the
occurrence of hyperfiltration and of glomerular hypertension in experi-
mental models. Atrial natriuretic factor (ANF) is a natriuretic and
vasodilating hormone. The most striking hemodynamic renal effect of
ANF is the increase in glomerular filtration fraction (FF) due to preglo-
merular vasodilation and postglomerular arteriolar constriction. In IDDM
increased levels of ANF have been found. Infusion of ANF in a low dose
causes diuresis, natriuresis and an increase of FF. We hypothesize that
infusion of low dose ANF will increase FF in uncomplicated type 1
diabetic patients and will induce (micro)albuminuria without an influence
on systemic blood pressure. In 48 normotensive uncomplicated type 1
diabetic patients we investigated the effect of ANF infusion (dose steps
0.01 and 0.02 jzg/kg/min) on glomerular filtration rate (GFR), effective
renal plasma flow (ERPF), FF, urinary albumin excretion and blood
pressure. GFR and ERPF were measured by inuline and PAH clearance
periods of 20 mm. Albuminuria was measured by an ELISA. Blood
pressure was recorded by dinamap. Data were analyzed by repeated
measures of ANOVA. Results are expressed as means SEM. GFR was
120 2 ml/min/1.73 m2 at baseline and increased dose related during
ANF infusion to 122 2 and 129 2 (P < 0.01). ERPF was 565 16
ml/min/1.73 m2 and decreased to 514 14 and 502 15, respectively,
during ANF infusion (P < (1.01). As a consequence FF increased from
21.7 0.5 to 24.2 0.5 and 26.3 0.6. Neither mean arterial pressure nor
heart rate changed during ANF infusion. Basal albumin excretion was
6.8 0.6 and increased to 18.7 1.7 and 53.7 5.9 jrglmin (P < 0.01).
During the first ANF dose (0.01 .tg/kg/min) urinary albumin excretion was
>20 g/min in 14 out of 46 subjects whereas this was 31 out of 39 during
the second dose (0.02 rg/kg/min). It is concluded that ANF infusion in low
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dose increases glomerular capillary pressure and induces (micro)albumin-
uria in normotensive uncomplicated type 1 diabetic patients without a
significant influence on systemic blood pressure. The hemodynamic
changes induced by ANF infusion mimic the functional changes seen in
microalbuminuric patients with IDDM. Therefore, it is suggested that
infusion of ANF could uncover the susceptibility to (incipient) nephrop-
athy in IDDM.
Direct evidence for resetting of baroreceptor mediated sympathetic
activity by enalapril in chronic renal failure. P.1. Blankestijn, G. Ligten-
berg, L. T. Dijkhorst, P.L. Oey, G. Wieneke, HA. Koomans, Departments of
Nephrology and C/in Neurophysiology, University Hospital Utrecht, The
Netherlands. In patients with chronic renal failure (CRF) increased
sympathetic activity has been reported. This may be due to stimulation of
afferent renal nerve activity, and angiotensin II production, both a result
of renal ischemia. It is uncertain whether increased sympathetic activity,
next to renin and volume, plays a role in hypertension, and whether this
requires separate therapeutic measures. Since ACEi also reduces central-
ly-acting angiotensin II, we hypothesized that ACEi may reduce sympa-
thetic activity, despite concomitant reduction of blood pressure. In ten
patients (age range 36 to 61 years, CRF due to various non-diabetic
causes, creatinine clearance 14—63 mI/mm), sympathetic activity mea-
sured by microneurography of the peroneal nerve (muscle sympathetic
nerve activity, MSNA, expressed in bursts/mm), and baroreceptor sensi-
tivity [subsequent infusion of nitroprusside (SNP) and phenylephrine
(PE)1 were assessed in three sessions: without ACEi, during chronic ACEi
treatment (5 to 10 mg enalapril), and again without ACEi. During the first
session, the effect of acute enalaprilat (5 mg i.v.) was measured as well.
Without ACEi, mean arterial pressure (MAP) and baseline MSNA were
increased in the patients as compared to normals: 119 15 vs. 80 11
mm Hg (P < 0.001) and 29 11 vs. 14 4 bursts/mm (P < 0.001). After
at least 4 weeks of ACEi, MAP was reduced from 119 15 to 98 14 mm
Hg (P < 0.005), and MSNA from 29 11 to 22 10 bursts/mm (P <
0.005). The haroreceptor curve under ACEi was shifted leftward, with an
unaltered slope. The results of the third session were identical to those of
the first, with a curve completely shifted back to the original position.
Acute enalaprilat reduced MAP with 12 5 mm Hg in four patients.
MSNA did not change, while in the same patients an identical decrease in
MAP with SNP resulted in an increase of MSNA of 58 29%. tn
conclusion, this is the first study providing direct evidence in CRF patients
that chronic ACEi shifts baroreceptor-mediated sympathetic activity to a
lower blood pressure level. Acute reduction in blood pressure by ACEi
does not result in an increase in MSNA, as opposed to other vasodilating
agents. These effects may contribute to the antihypertensive efficacy of
these drugs and may lessen the adverse consequences of sympathetic
overactivity on cardiovascular function and structure in CRF.
Improved dialysis efficiency during acetate free biofiltration. AM.
Schrander-v.d. Meer, P.M. t. Wee, A.J.M. Donker, W. T v. Dorp, Kennemer
Gasthuis location EG, Haarlem & Free University Hospital, Amsterdam, The
Netherlands. Acetate free biofiltration (AFB) is a hemodiafiltration tech-
nique based on continuous postdilution infusion of a sterile isotonic
bicarbonate solution. Many advantages including better metabolic control
have been described, mostly in short term studies. We performed a
long-term prospective randomized trial to compare dialysis efficiency and
metabolic control of AFB versus bicarbonate hemodialysis (HD). The
AFB group consisted of 11 and the HD group of 9 patients, matched for
age, sex and ureum reduction rate. During one year every three months
biochemical results were obtained. Statistical analysis was performed using
ANOVA for repeated measurements. Throughout the study period Ca, P,
Hh and erythropoietin dosage did not change in both groups and no
significant changes between the two groups were present. For AFB
patients the infusion rate of bicarbonate solution was adjusted individually
to obtain optimal values of HCO1 (before dialysis 22 mmol/liter and
after dialysis 32 mmol/litcr). In the HD group the HC03 was added as
oral medication to match for HC03 concentrations. In both groups
HCO3 increased during the study period to the same extent (P < 0.001).
In AFB patients KT/V increased from 2.73 to 3.17 (P < 0.04). In HD
patients KTIV did not change (P < 0.38), the difference between groups
being significant (P < 0.013). Finally, PTH increased in both groups (AFB
from 10.6 to 23.7 pmol/liter and HD from 24.6 to 32.8 pmol/litcr), but only
the rise in AFB patients was significant (P < 0.04). In conclusion, we
demonstrated that dialysis efficiency, measured as Kt/V, improved during
AFB. The observed increase in PTH remains to be clarified.
Molecular cloning of the human thiazide-sensitive sodium-chloride
cotransporter (NCCT) and identification of mutations in patients with
autosomal-recessive Gitelman syndrome. H.H. Lemmink, L.P. WJ. van
den Heuvel, HA. van Dijk, GEM. Merla, T Smilde, P.E.M. Taschner, S.C.
Hebert, L.A.H. Monnens, and NA. V.M. Knoers, Departments of Pediatrics,
Internal Medicine and Human Genetics, University Hospital Nijmegen,
Nijmegen, Department of Human Genetics, University of Leiden, Leiden, The
Netherlands, and Renal Division, Brigham and Women's Hospital, Boston,
Massachusetts USA. Gitelman syndrome is a mostly autosomal recessive
disorder affecting the renal tubular function associated with hypokalemia
and hypomagnesemia. Functional studies point to a defect in the distal
renal tubule in a recently cloned thiazide-sensitive, electroneutral sodium
chloride cotransporter (NCCT). A 2.6 kb human NCCT eDNA probe was
isolated by RT-PCR from human kidney and used for hybridization to a
panel of somatic cell hybrids and in FISH analysis. The human NCCT
gene was mapped to chromosome 16q12-13 and polymorphic markers
from this region were tested for linkage to the Gitelman's syndrome locus
in families with autosomal recessive inheritance of this disorder. Using
two-point linkage analysis a maximum LOD score (Zmax) of 4.49 (at e =
0.0) was found for the marker D16S408. To identify mutations in our
group of 16 unrelated Gitelman patients, we performed RT-PCR on RNA
isolated from lymphoblastoid cell lines or PCR-SSCP analysis on individ-
ual NCCT exons, followed by direct sequence analysis of amplified NCCT
DNA fragments. After screening about 60% of the NCCT coding region
a total of seven mutations (hetero- or homozygous) have been identified
in 9 unrelated Gitelman patients including four missense, two splice site
and one nonsense mutation. Five of these mutations are found in more
than one Gitelman family probably indicating that these patients have a
common ancestor. The functional effect of identified NCCT mutations on
sodium-chloride transport is studied through measurement of 36Cl uptake
by Xenopus leavis oocytes after injection with normal and mutant NCCT
cRNA.
Decrease of GBM heparan sulphate staining and albuminuria in
adriamycin nephropathy in rats is partly mediated by hydroxyt radicals.
C.J.1. Raats, M.A.H. Bakker, J. van den Born and J.H.M. Berden. Division of
Nephrology, University Hospital Nijmegen St. Radboud, Nijmegen, The
Netherlands. Heparan sulphate proteoglycan (HSPG) is thought to be
important for the permeability properties of the GBM. We studied the
GBM HSPG expression during the development of adriamycin (ADR)-
nephropathy with four different antibodies against various domains of
HSPG. ADR-nephropathy was induced in rats by a single i.v. injection of
5 mg ADR/kg body wt. Progressive albuminuria developed from 1 week
after the injection and increased to 438 54 mg/24 hr at week 5. Although
the GBM staining intensity of mAbs against the HSPG core protein and
the heparan sulphate (HS) stubs after heparitinase digestion remained
normal, ADR induced a decrease in staining of two antibodies directed
against different domains in the HS polysaceharide side chain of 32% and
48%, respectively (P = 0.03). Moreover, there was a significant inverse
correlation between albuminuria and GBM HS staining (r = —0.83; P =
0.0001), which suggests a functional relationship, although it is not clear
whether the HS decrease is cause or effect of the albuminuria. Because
reactive oxygen species (ROS) are implied as a mechanism for ADR
toxicity, we studied the effect of treatment with ROS scavengers on
albuminuria and GBM HS staining in rats with ADR-nephropathy.
Dimethyithiourea (DMTU), a scavenger of hydroxyl radicals, significantly
reduced ADR-induced albuminuria by 37% (from 356 111 to 224 79
mg/24 hr; P 0.01) and partly restored GBM staining of both anti-HS
mAbs by 35% and 32%, respectively (both P = 0.03). In contrast,
superoxide dismutase, which catalyses the degradation of superoxide
anion, had no effect on these parameters. From these findings we conclude
that ADR induces albuminuria and alterations in the polysaccharide side
chains of HSPG. Furthermore, the decrease of GBM HS staining corre-
lates with albuminuria and both pathological changes are (partly) medi-
ated by hydroxyl radicals. Since HS has been implicated in glomerular
filtration, we suggest hydroxyl radicals to depolymerize HS resulting in loss
of GBM integrity and albuminuria.
Danaparoid lowers proteinuria in diabetic nephropathy. J. W. van der
Pzj4 F.J. van der Woude, H.H.P.J. Lemkes, L.A. van Es, Departments of
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Nephrology and Endocrinology, Leiden University Hospital, Leiden, The
Netherlands. Diabetic nephropathy is a progressive renal disease with
mesangial expansion and proliferation as histological hallmarks. The
presence of heparan sulphate proteoglycan, an important constituent of
the glomerular basement membrane, is decreased in diabetic nephropathy
proportionally to the degree of proteinuria. Danaparoid is a mixture of
LMW sulphated glycosaminoglycans (GAGs), consisting mainly of hepa-
ran sulphate (—84%). We performed a randomized placebo-controlled
crossover study with danaparoid in diabetic patients with overt protein-
uria. The aims for the study were to evaluate putative effects on protein-
uria and safety/tolerability. Nine patients completed, without major side-
effects, the crossover study consisting of two 6-week periods of treatment
with 750 anti-Xa units of danaparoid s.c. once-daily or placebo. A
significant decline of both albuminuria and proteinuria was found. After
danaparoid the albumin excretion ratio corrected for creatinine reduced
with 17% in comparison with an increase of 23% after placebo (95% CI of
the difference —75.9%, —3.9%; P = 0.03). The percentual change of the
urinaly protein excretion corrected for creatinine differed at 8 weeks
significantly between both treatment arms (P = 0.001).Additional param-
eters for safety as hematology, hemostasis, biochemical and funduspho-
tography did not show any clinical significant difference for both groups.
Only two patients had minor skin hematomas while using danaparoid. In
conclusion, we found the supplementation was feasible and not associated
with side-effects. A significant decline of proteinuria was found. More
prospective dose-finding and long-term studies have to be performed to
see whether heparan sulphate could indeed not only induce a reduction of
proteinuria, but also halt the progression of renal disease.
An impaired renal hemodynamic response to a Di-agonist but not to a
D2-agonist in spontaneously hypertensive rats (SHR). PAM. de Vries,
G.J. Navis, AC. Kiuppel, P.E. de Jong, and D. de Zeeuw, GIDS, University
Hospital, Groningen, the Netherlands. Several investigators provided evi-
dence suggesting that a defect in the dopamine 1 receptor-mediated signal
transduction pathway in the proximal convoluted tubule in SHR plays a
role in initiation of hypertension in this animal model. Whether renal
hemodynamic responses to dopaminergic stimuli are also defective in
SHR, is unknown. In the present study we therefore investigated the effect
of a continuous infusion of the Di-agonist fenoldopam (FD; 2 jLg/kg/min)
and D2-agonist dipropyldopamine (DPDA; 10 jzglkglmin) on systemic and
renal hemodynamics (clearances of 251-iothalamate and '311-hippuran,
respectively) in conscious chronically instrumented SHR and WKY rats.




ml/min 100 g body wt %
WKY baseline 94 12 2.97 0.45 0.83 0.10 28 3
(N = 9) FD 90 T 3.36 0.82a 0.82 0.10 25 4
SHR baseline 146 17 2.74 1.13 0.80 0.14 31 5
(N = 10) FD 132 24 2.70 0.9 0.77 0.12 30 5
WKY baseline 87 8 2.81 0.66 0.71 0.11 26 4
(N = 10) DPDA 82 8 2.52 0.55 0.67 0.l0' 27 a
SHR baseline 143 10 2.58 0.47 0.72 0.09 28 3
(N = 9) DPDA 134 iia 2.14 0.28k' 0.68 0.OT 32 3
a P < 0.05 versus baseline (paired t-test)
During fenoldopam and DPDA MAP fell in both SHR and WKY rats.
The renal hemodynamic response to fenoldopam was different for the two
strains. In WKY rats fenoldopam caused an increase of the ERPF of 13%
and a reduction in FF of 12%. In SHR, ERPF was not responsive to
fenoldopam. DPDA in contrast, caused a decrease in ERPF and GFR in
both strains, resulting in a rise in FF. En conclusion, the renal hemody-
namic response to fenoldopam but not to DPDA is impaired in SHR. The
systemic hemodynamic response to fenoldopam, as well as the renal and
systemic response to DPDA were similar in both strains. This finding
suggests a selective Di-receptor defect in the renal vasculature of SHR.
Whether this impaired renal hemodynamic Dl response contributes to the
pathogenesis of hypertension in the SHR remains to be investigated.
Is ACE inhibition superior to conventional antihypertensive therapy in
retarding progression in non-diabetic renal disease? G. G. van Essen,
A.J. Apperloo, W.J. Sluiter, D. de Zeeuw, P.E. de Jong, University Hospital,
Groningen, The Netherlands. Several investigators have advocated the use
of ACE inhibitors to retard the progressive loss of renal function in
diabetic as well as in non-diabetic nephropathy. In a prospective double-
blind trial we compared the effect of the ACE inhibitor enalapril and the
beta-blocking agent atenolol on the decline of GFR, as measured by 125J
iothalamate. In total 89 patients (57 men and 32 women, mean age 49.5
years) with renal insufficiency (mean baseline GFR 53 mI/mm) due to
various non-diabetic nephropathies were analyzed.
Atenolol
(N=46) Enalapril(N=43)
Baseline SBP mm Hg 153 3 151 3
Baseline DBP mm Hg 90 3 90 3
Baseline protein g/day 1.9 0.4 1.2 0.3
Follow-up SBP mm Hg 135 3 134 3
Follow-up DBP mm Hg 80 2 78 ia
Follow-up protein g/day 1.5 0.3 0.9 0.2
GFR slope mI/mm/year —1.4 0.4 —2.0 0.5
Data are mean SEM, a Significant compared to baseline (P < 0.05)
Baseline characteristics were not significantly different. After a 3—4 week
run-in period antihypertensive therapy was started aiming for a 10 mm Hg
fall in diastolic blood pressure. DBP was kept constant during a mean
follow up of 3.6 years. Blood pressure control was equal. No significant
difference was observed in GFR slope between the treatment groups, and
also not in creatinine clearance and the reciprocal of serum creatinine.
The slopes were comparable to those of a normal population. In addition,
we calculated the type II error chance of missing a benefit for enalapril to
be less than 1.25%. We conclude that use of ACE inhibitors is not
imperative in all renal patients. Such advice at present is valid only for
patients with increased risk, such as those with significant hypertension
and/or proteinuria.
Antigen-antibody complexes enhance the production of complement
component C3 by human mesangial cells. J.J. Timmerman, D.J. van
Gijlswzjk-Janssen, S. W. van der Kooij, L.A. van Es, and MR. Daha,
Department of Nephrology, Leiden University Hospital, Leiden, The Nether-
lands. Deposition of immune complexes, in the presence or absence of
various complement components, occurs in many forms of glomerulone-
phritis. Furthermore, it has been reported that local production of
complement occurs both in normal kidneys and that mRNA for a number
of complement components is enhanced during inflammation, suggesting
that local production of complement may occur at various sites in the
kidney. We have shown previously that human renal mesangial cells (MC)
express receptors for IgG and IgA and that these cells produce, for
example, complement component C3 under resting conditions. Enhanced
production of C3 was shown to occur in the presence of inflammatoiy
cytokines such as IFN7 and IL-i. Since mesangial cells express FCR III in
culture, we have questioned whether MC, when exposed to IgG-contain-
ing immune complexes, would exhibit an altered pattern of complement
production. Therefore, MC were cultured in medium alone or in medium
with insoluble heat-aggregated rat IgG (AIgG), as a model for ICX, or
with insoluble immune complexes (ICX) and assessed for C3 and factor H
production. Basal production of C3 and factor H were 10 1 ng/106 cells
and 605 15 ng/106 cells/72 hours, respectively. The presence of 400
tg/ml ICX resulted in an up-regulation of C3 production to 999 15
ng/106 cells/72 hours and 510 1 ng/106 cells, respectively, while no
significant change in factor H production was observed. The up-regulation
of C3 synthesis was both time- and dose-dependent and inhibitable by
cycloheximide, suggesting that de novo protein synthesis was required. By
RT-PCR and Northern blot analysis it was demonstrated that C3 and IL-6
mRNA expression were up-regulated in MC following incubation with
AIgG. No significant change in factor H mRNA expression was observed.
Furthermore, it was shown by RT-PCR analysis that the MC used for the
experiments expressed FcyRIII mRNA. Incubation of the MC with
F(ab1)2-fragments or with rabbit IgG alone did not result in increased C3
synthesis, suggesting that crosslinking of the FcyR's on MC is necessary
for the enhancement of C3 production. In conclusion, it is shown in the
present study that triggering of FcyR on MC by AIgG or ICX not only
results in up-regulated production of inflammatory mediators such as
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cytokines, but also in up-regulated synthesis of complement component
C3. Therefore, we hypothesize that complement produced locally, may
enhance removal of locally formed immune complexes and thereby lead to
protection against inflammation. However, enhanced generation of com-
plement fragments on the other hand could also lead to increased
inflammation.
Discontinuation of mycophenolate mofetil treatment six months after
kidney transplantation. T. van Gelder, J.N.M. Yzermans, J. Rischen-Vos,
W Weimar, Department of Internal Medicine I and Surgeiy, University
Hospital Rotterdam, Rotterdam, The Netherlands. In three large random-
ized trials it has been shown that the incidence of acute rejection after
kidney transplantation can he reduced with 50% by adding mycophenolate
mofetil (MMF) to cyclosporine (C5A) and prednisone as an immunosup-
pressive treatment. However, it is unclear how long this triple drug
treatment should be continued. As long as data on prevention of chronic
rejection in MMF treated patients are not available, continuation of triple
drug treatment for years after transplantation may lead to over-immuno-
suppression. We report on a group of kidney transplant recipients in
whom MMF administration was stopped 6 months after transplantation.
In our center 25 first or second kidney transplant recipients were entered
into a randomized, double-blind, concentration-controlled, multi-center
trial examining the effect of MMF on the prevention of acute rejection
between June 1994 and March 1995. All patients were treated with CsA
and prednisone, combined with MMF in three different dosage groups
(500 mg b.i.d., 1200 mg b.i.d., 2000 mg b.i.d.). Seven patients did not
comply with the protocol and were excluded from the study. One patient
developed a severe acute rejection and lost his graft one week after
transplantation. In all other 17 patients MMF was stopped after a mean of
160 days. None of them was complicated by acute rejection. In 9 of 17
patients CsAlprednisone maintenance immunosuppression was converted
to azathioprine/prednisone 3 to 10 months after stopping MMF. All 17
patients arc alive with stable graft function. In conclusion, MMF treat-
ment during the first 6 months after kidney transplantation results in
stable engraftment, allowing MMF to be withdrawn and CsAlprednisone
maintenance treatment to be converted into azathioprine/prednisone.
Long-term continuation of triple drug treatment (CsA/pred/aza) does not
seem necessary.
Induction of experimental proteinuria in viva following infusion of a
human plasma factor associated with Minimal Change Disease (MCD).
P.K. Cheung, PA Klok, and W. W. Bakker, Department of Pathology,
University of Groningen, Groningen, the Netherlands. Circulating factors,
including the plasma protease IOOKF described previously, are believed to
play a role in the pathogenesis of MCD. Perfusion of IOOKF into the rat
kidney resulted in increased urinary protein excretion associated with
MCD-like histochemical changes. To investigate 100KF activity in vivo, we
now studied proteinuria following direct renal infusion in conscious
(experiment A) as well as in anesthetized rats (experiment B). Experiment
A: a permanent cannula was surgically inserted into the suprarenal artery
(SRA), enabling continuous infusion into conscious animals (N = 6). At
day I, control fraction (that is, BSA; 4 mg in 5 ml saline) was infused
during 15 minutes, followed by saline (5 ml/hr) for 7 hours. Urine samples
were collected and proteinuria was monitored during 24 hours. At day 2,
identical procedures were carried Out in the same animal, using IOOKF
infusion instead of BSA. In experiment B, unilateral kidney perfusion in
the blood-free kidney, followed by reconnection of the circulation was
carried out in anesthetized rats according to standard procedures. The
kidney was perfused with either 100KF (N = 5) or BSA (N = 3) (both 1.5
mg/mI; 4 ml) during 6 minutes. Separate urine samples of both kidneys
were collected via ureter cannulation every 30 minutes daring 5 hours.
Proteinuria (in mg124 hr) is expressed as the difference in the urinary
protein excretion between the perfused and the non-perfused kidney. The
results show a significant increase of proteinuria after infusion of IOOKF
into the SRA as compared to animals infused with BSA (41.91 16.01
mg/24 hr vs. control: 21.22 5.69 mg124 hr; P  0.03). Also, increased
excretion of urinary albumin, in contrast to IgG, was measured: Albumin
was 1.85 2.24 mg/24 hr vs. 0.04 0.10 mg/24 hr (P 0.03), and IgG was
3.48 1.88 mg124 hr vs. 2.26 1.27 mg124 hr (NS) after infusion with
100KF and BSA, respectively. Unilateral kidney perfusion of 100KF (in
Contrast to BSA) into anesthetized rats resulted in peaking of urinary
protein showing a maximum at t = 1 hour (6.63 7.06 mg/24 hr; P
0.001). It is concluded that the plasma protease 100KF is capable to
promote proteinuria in vivo.
Losartan, an angiotensin-Il (Ang H) receptor antagonist, reduces
hematocrits (Hct) in patients with post-transplant erythrocytosis (PTE).
R.J.L. Klaassen, T van Gelder, J. Rischen-Vos, J. Deinum, A.J. Man in 't
Veld, and W Weimar, Department of Internal Medicine I, University Hospital
Rotterdam, Rotterdam, The Netherlands. PTE occurs in 10—15% of the
patients with a well-functioning kidney transplant and is associated with an
increased risk for thrombo-embolic complications. Although the pathoge-
netic mechanism of PTE is not yet known, PTE responds in most patients,
but not in all, to inhibition of ACE. Because ACE-inhibitors (ACE-i)
frequently show side-effects and to elucidate by which pathway ACE-i
mediate their effect in PTE, we treated 8 patients (5 with newly diagnosed
PTE, 2 with PTE unresponsive to ACE-i, 1 with PTE responsive to ACE-i,
that had to be withdrawn due to side-effects) with 50 mg of losartan. PTE
was defined according to accepted criteria. Hct values in the 2 patients
who were unresponsive to ACE-i did not change significantly during 10
weeks of treatment. In contrast, Hets decreased in all other 6 patients on
losartan: 0.53 0.02 to 0.50 0.03 (P < 0.02) and to 0.46 0.03 (P <
0.005) at 3 and 6 weeks, respectively (mean SD; paired t-test). Neither
blood pressure (adapted antihypertensive regimen in some patients) nor
serum values of creatinine and potassium nor leukocyte and platelet count
changed significantly during treatment. Losartan is effective in treating
PTE in a majority of our patients and is suggested as the drug of choice to
treat PTE. Two patients with PTE unresponsive to ACE-i also did not
respond to losartan. Ang II and the Ang II receptor type I appear to be
involved in dysregulated erythropoiesis in renal transplant recipients.
Urea kinetics studied by i.v. bolus injection of '3C urea in the
interdialytic interval of hemodialysis patients. W.D. Kloppenburg, CA.
Stegeman, P.E. de Jong, and R.M. Huisman, Department of Nephrology,
University Hospital, Groningen, The Netherlands. Characterization of urea
transport and distribution by formal pharmacokinetie analysis in hemodi-
afysis patients has rarely been done due to inconvenience and expense of
the hitherto available methods. We developed a new method which
applies small amounts of 13C urea that are subsequently measured by gas
chromatography and isotope-ratio mass speetrometly, so that urea metab-
olism can easily be studied in more detail. With this method we studied the
kinetics of urea after a bolos i.v. injection of 0.8 mmol '3C urea in 7 stable
anuric hemodialysis patients during the interdialytic interval. A two
compartment model provided a good fit of the data. It yielded an apparent
volume of the central compartment of 20.9 6.2 (SD) liter and an
apparent volume of the peripheral compartment of 19.4 6.0 liter, the
central volume ranging from 40—52% of the total volume in 6 of the
patients, whereas the percentage was 85% in 1 patient. The half-life time
of the fast component of the concentration-time curve varied between 10.1
and 18.7 minutes (mean 14.5 2.7 minutes). The clearance from central
to peripheral compartment and vice versa was 455 125 mI/mm and
452 123 mI/mm, respectively. The endogenous whole body urea
clearance varied from 0.3—10.5 ml/min (mean 5.8 4.1) in these anuric
patients. We conclude that the central and peripheral urea compartments
are about equal in size. This is incompatible with the notion that these
compartments reflect extra- and intracellular water. It is also incompatible
with the recent hypothesis that the compartmental behavior of urea is due
to a small volume of body water being in highly perfused organs and a
large volume in slowly perfused tissue since in that case the fast central
compartment would he expected from the literature to be about 20% of
the total urea distribution volume. This indicates that the calculated
volumes are virtual and do not represent clear-cut physiological entities.
For practical purposes the half-life times found in the current study mean
that a waiting period of more than half an hour is usually required to
obtain an equilibrated urea sample after dialysis.
Possible role for CD4O-CD4OL in the regulation of interstitial infiltra-
tion in the kidney. C. van Kooten, .1.S.J. Ge,ritsma, ME. Paape, L.A. van Es,
J. Banchereau, and MR. Daha, Department of Nephrology, Leiden University
Hospital, Leiden, the Netherlands; and Laboratory for Immunological
Research, Schering Plough, Dardilly, France. Interstitial infiltration by
mononuclear cells is a hallmark of most inflammatory kidney diseases, and
the degree of infiltration is associated with disease progression. It has been
demonstrated that proximal tubular epithelial cells (PTEC) are an impor-
tant source of different eytokines/chcmokines and thereby play a central
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role in the regulation of the local inflammatory response. CD4O is a cell
surface receptor involved in immune regulation, for which the ligand is
expressed on activated T cells. By different staining methods, CD4O was
found expressed in cryosections on the basolateral side of tubuli, as well as
on the surface of an SV4O-transformcd PTEC line and on primary PTEC
cultures. Crosslinking CD4O receptor on these cultured cells, using a
CD4OL-transfected mouse fibroblast, resulted in strong up-regulation of
the production of the chemokines IL-8, MCP-1 and RANTES. For IL-8
and MCP-1 production, the stimulation index after CD4O activation
ranged from 2 to 7-fold. Much stronger effects were observed for
RANTES production, where levels remained undetectable (<0.1 nglml)
in non-stimulated cultures, whereas CD4O activation resulted in a strong
production reaching 5 ng/ml in a 72 hour culture period. These data
suggest that CD4OL-CD4O interactions between infiltrating activated T
cells and PTEC might be an important factor in the regulation of
interstitial infiltration within the kidney.
Unsulfated heparan sulfate domains are demonstrated in normal GBM
and renal fibrosis by a monoclonal antibody. I van den Born, C.J.L Raais,
KJ.M. Assmann, K Jann, U. Lindahl, and J.H.M. Berden, Division of
Nephrology and Department of Pathology, University Hospital Nijmegen,
Nijmegen, The Netherlands; Max-Planck-Institut für Immunbiologie,
Freiburg, Germany; Department of Medical and Physiological Chemistry,
University of Uppsala, Uppsala, Sweden. Heparan sulfate (HS) is the
polysaceharide side chain of heparan sulfate proteoglycan (HSPG) and is,
in addition to glomerular filtration, involved in cell growth, adhesion,
differentiation, and transformation. It has been reported that N-acetylated
HS domains can inhibit cell proliferation and angiogenesis. Recently, we
described a monoclonal antibody, coded KJ865, which recognizes ex-
tended unsulfated N-acetylated domains in HS. Immunofiuorescence
experiments on rat and human kidney cryostat sections revealed staining
of the GBM and the basal laminae of vascular smooth muscle cells.
Tubular basement membrane staining was variable; no interstitial staining
was observed. In rats with established Adriamycin nephropathy, GBM
staining with KJ865 was clearly diminished, whereas the expression of the
HSPG core protein did not change. In areas of interstitial fibrosis an
up-regulation of the KJ865 epitopes was found. In human transplant
kidneys with chronic vascular rejection (N = 8) these unsulfated HS
domains were predominantly found in areas with periglomerular, intersti-
tial and arterial intima fibrosis. In 4 biopsies chronic transplant glomeru-
lopathy was found with variable expansion of the mesangial matrix, which
was strongly positive for KJ8bS. Focally, a decreased 1(1865 staining was
observed within the tubulo-interstitium and in the GBM. We speculate
that KJ865 positivity may represent a pooi of immobilized precursors of
anti-proliferative and anti-angiogenic HS oligosaccharides, which can be
liberated under certain conditions due to depolymerization by endoglyco-
sidases or oxygen radicals. Loss of 1(1865 staining can be the result of such
mechanisms, or might be due to an altered sulfation pattern of HS.
Induction of hematuria by mouse IGA anti-THY1.I monoclonal anti-
bodies in rats. M.G.A. van Dixhoom, A. Goner, T Sata, A.M Van der Wal,
J.D.H. van Eendenburg, I Razing, MR. Daha, and E. de Heer, Department
of Nephrology and Pathology, University Hospital Leiden, University of
Groningen, The Netherlands. IgA nephropathy (IgAN) is a chronic form of
glomerulonephritis (GN) characterized by glomerular deposition in the
mesangium of mainly polymeric IgA (pIgA). An experimental comple-
ment dependent form of mesangial proliferative ON can be induced in
rats by anti-Thyl.1 antibodies. Thyl.1 is a glycoprotein present on the
surface of mesangial cells (MC). Rats develop GN similar to acute
mcsangial proliferative ON in humans. In the present study we have
switched an lgG2a anti-Thy-l.l (ER4G) producing hybridoma to an IgA
anti-Thy-1.1 (ER4A) producing clone and analyzed the effects of IgA
anti-Thy-1.1 in rats. Administration of ER4G (1 mg/kg) resulted in
proteinuria reaching levels of 300 mg protein/24 hours on day 3. No
significant urinary protein excretion was found in rats treated with
pER4A. However, significant microhematuria was observed in rats receiv-
ing either ER4A or ER4G as assessed by direct enumeration of erythro-
cytes in urine, dipsticks and a colorimetric method for hemoglobin. The
observed erythrocyturia corresponded well with the number of erythro-
cytes observed in the lumen of renal tubules. The administration of ER4A
was not accompanied by activation of complement and no significant
influx of monocytes or polymorphonuclear leukocytes in contrast to the
rats receiving ER4G. Even upon administration of a tenfold higher dose
of pER4A (10 mg/kg) no histological abnormalities or signs of inflamma-
tion were observed. We conclude that in this model for IgAN a selective
microhematuria is induced in Wistar rats by mouse IgA anti-Thy-1.1
without detectable complement-mediated injury to MC. These studies
may be of importance for our understanding of the mechanisms leading to
IgAN in patients.
Mis-i incompatible donor thymocytes down-modulate the development
of murine chronic Graft-versus-Host disease. M Sutmuller, II Baelde,
P2. de Heer, and J.A. Bmijn, Department of Pathology, Leiden University,
Leiden, The Netherlands. Susceptibility to systemic lupus erythematosus
(SLE) and, in particular, lupus nephritis is strongly influenced by genetic
factors. Chronic Graft-versus-Host disease (GvHD) in mice is a model for
lupus nephritis which results from a delicate interplay between donor and
recipient lymphocytes. One of the main features of this disease is the
development of polyclonal B-cell activation resulting in the deposition of
immune complexes (IC's) along the glomerular capillary wall and the
development of proteinuria. We previously described that the incompat-
ibility between donor and recipient in Mls1a induced a rapid self-
limitation of the GvHD. To induce GvHD, we injected a mixture of
BALB/c (MIs-i5) thymocytes, splenocytes and lymphocytes into
Balb.D2 x BL1O (Mts-I1') Fl hybrid recipients. To investigate the role of
thymocytes in the self-limiting GvHD, GvHD was induced in a subsequent
experiment using splenocytes and lymphocytes alone as donor cells in the
same strain combination. To correct for the lack of thymocytes the amount
of injected splenocytes and lymphocytes was adjusted. In a separate
experimental group of recipients, receiving both thymocytes and lympho-
cytes, the animals did not develop proteinuria and no IC's were detectable
in the glomerulus 8 weeks after induction of GvHD. In contrast, in the Fl
hybrids in which thymocytes were omitted from the injected cells, IC's
were clearly visible by IF. Proteinuria developed from 8 weeks after
induction of disease. Our study indicates that Mis-I incompatibility
between donor and recipient may activate thymic donor T-cell precursors
that arc able to induce a self limitation of allogeneic disease by prevention
of polyclonal B-cell activation.
T-cell receptor Vfi repertoire in murine chronic Graft-versus-Host
disease. M Sutmuller, J.J. Baelde, E. de Heer, and J.A. Bndjn, Department
of Pathology, Leiden University, Leiden, The Netherlands. In a number of
autoimmune diseases a preferential involvement of T-cell receptor (TeR)
Vf3 genes has been postulated. This limited TcR V3 repertoire employed
by infiltrating T-cells may be related to the development and course of
these autoimmune diseases. A restricted TeR V repertoire has been
reported in animal models in which mice spontaneously develop systemic
lupus erythematosus (SLE), that is the MRL/lpr and the NZB/W mice.
Murine chronic Graft-versus-Host disease (GvHD) is an experimental
model for SLE, which is induced by transfer of parental lymphocytes into
Fl hybrid recipients. Subsequent polyclonal B cell stimulation results in
autoantibody production and autoimmunity. In addition to this atloreac-
tion, rctroviral supcrantigcns, such as minor lymphocyte stimulating (MIs)
antigens, may play an important role in the onset and the regulation of the
GvHD. Intra-thymic expression of the MIs superantigen causes a deletion
of T cells with certain Vp's and a reduced TcR repertoire in the periphery.
Absence of MIs, during T-cell development, results in a larger V/I
repertoire of T-cells. In GvHD, this incompatibility between strains of
mice with or without Mls can be used to determine preferential involve-
ment of certain TcR V/I families. In this study we investigated which TeR
V/I genes are preferentially expressed by expanding T-cells during the
development of the GvHD. Secondly, the effect of MIs incompatibility
between donor and recipient was studied. For these purposes we used
combinations of mouse strains which differ only in non-H2 and MIs. The
GvHD was induced by injection of parental (H-T') cells into Fl hybrids of
C57BL1O (H-2" Mls-1") with BALB/c (H-25, Mls-15) or Balb.D2 (H-25,
Mls-Y') mice. The V/I expression was determined in spleen tissue with the
RNase protection assay. MIs-P incompatibity causes a self limitation of
the GvHD. In our Mis-U' strain combination we saw an increased
expression of V/33.1 in the first two weeks of the GvHD. During the
development of GvHD in the Mis-P compatible strain combination we
saw an increase in V/32 expression, while in the incompatible strain
combination this expression was decreased. In conclusion, T-cells bearing
the TeR Vj32 chain may play a role in GvHD development, while T-cells
bearing V/33.l may be important in self limitation of the GvHD.
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Expression of granzyme B by an activated apoptosis-prone CD8 T
lymphocyte subset. P.C. Wever, if, van der l7iet, AM. Wolbink-Kamp,
L.H.A. Spaeny-Dekking, J.J. Weening, C.E. Hack, and R.J.M. ten Berge,
Academic Medical Center, Departments of Internal Medicine and Pathology,
and Central Laboratoty of the Netherlands Red Cross Blood Transfusion
Service, Amsterdam, The Netherlands. Granzyme B is a cytotoxic protein
stored in the granules of mature natural killer cells and activated cytotoxic
T lymphocytes. Granzyme B has been implicated in induction of apoptosis
in allogeneic target cells. Data concerning expression of granzyme B by
peripheral blood T lymphocytes are conflicting. We have produced
monoclonal antibodies (mAb) directed against recombinant granzyme B
which are suitable for immunocytochemistiy as well as mAb directed
against native granzyme B which are suitable for FACS analysis. Immu-
nocytochemical two-color stainings for expression of CD3 and granzyme B
were performed on cytocentrifuge preparations of peripheral blood
mononuclear cells (PBMC) from 10 healthy adults. Optimal immunostain-
ing was reached after fixation in buffered formalin followed by non-
enzymatic antigen retrieval in sodium citrate buffer. Expression of gran-
zyme B was detected in 9 1% (mean SCM) of CD3 T lymphocytes.
Three-color FACS analysis of saponin-permeabilized PBMC revealed the
granzyme B expressing CD3 T lymphocytes to reside primarily in the
CD8 subset. The activated status of CD8 T lymphocytes expressing
granzyme B is reflected by an increased expression of CD45RO and
HLA-DR, while the increased expression of Fas and Bax and the
decreased expression of CD28 and Bcl-2 indicate an enhanced suscepti-
bility to apoptosis. Therefore, we postulate that granzyme B expressing
CD8 T lymphocytes in peripheral blood of healthy adults represent a
subset of terminally differentiated T lymphocytes preparing for apoptosis.
Next, the presence of granzyme B expressing CD8 T lymphocytes in
peripheral blood of both stable renal transplant recipients and patients
with acute renal allograft rejection will be studied.
Expression and characterization of human perlecan domains I and II
synthesized by baculovirus-infected insect cells. A.J.A. Groffen, C.A. F.
Buskens, K Tiyggvason, J.H. Veerkamp, L.A.H. Monnens, and L.P. WI van
den Heuvel, Department of Pediatrics, University of Nijmegen, Nijmegen, The
Netherlands. We present the in vitro expression and purification of
N-terminal fragments of human perlecan in insect cells. Three "tailored"
fragments of human perlecan cDNA were introduced into the polyhedrin
locus of baculovirus expression vectors encoding domain I (fragment P1,
amino acids 1—196), domain I + II" (P12", amino acids 1—404), and
domains I + II" + ii" (P12"', amino acids 1—506). The integrity of the
BEVs was checked by DNA sequencing, polymerase chain reaction,
restriction enzyme analysis and Southern blotting. Northern hybridization
and metabolic labeling with [°5Slmethionine showed that expression of
domains I and II together was successful, but in the case of domain I only
no recombinant protein was produced. Immunoblotting showed that both
the P12" and P12"" fragments are recognized by 95J10, a monoclonal
antibody that was previously raised against perlecan fragment P12a
expressed in Escherichia co/i. Gel permeation and anion exchange chro-
matography were applied to purify the recombinant proteins. Glycosami-
noglycans were demonstrated to be present. Deglycosylation with chon-
droitinase ABC showed that the P12" fragment was glycosylated with
chondroitin sulfate residues. Consistent with these results, glycosamino-
glycans isolated from the P12' fragment were identified as chondroitin
sulfate by agarose gel electrophoresis. Furthermore, the P12" fragment
showed affinity to immobilized basic fibroblast growth factor. The avail-
ability of baculovirus-derived recombinant perlecan fragments will facili-
tate domain-specific investigation of the structural and functional proper-
ties of perlecan in the future.
The glomerular deposition of PAS positive material correlates with
renal function in human kidney diseases. L. -J. Vleming, J.J. Baelde, R. G.I
Westendoip, M.R. Daha, L.A. van Es, and J.A. Bruijn, Departments of
Nephrology, Pathology, and Clinical Epidemiology, University Hospital Lei-
den, Leiden, The Netherlands. General agreement exists on the correlation
of renal insufficiency with the severity of tubulointerstitial abnormalities in
the biopsy. This could not be shown for the severity of glomerular
pathology by semiquantitative methods. The relation between renal
function and glomerular pathology was therefore evaluated in patients
with various kidney diseases using quantitative measurements. Fifty-five
patients and ten controls were studied. Histomorphometric measurements
of renal biopsies were obtained for both frozen and paraffin sections and
were correlated with serum creatinine values. The frozen sections were
stained with an indirect immunopcroxidase technique using antibodies
against collagen types I, IV, V, VT, laminin, fibronectin, decorin and
heparansulphate proteoglycan core protein. The contribution of each
component to the composition of the mesangial extracellular matrix was
scored with a semiquantitative technique. All glomerular histomorpho-
metric indices correlated with the severity of renal insufficiency expressed
as serum creatinine at the time of biopsy. However, quantitative estimates
of the glomerular deposition of periodic acid-Schiff positive extracellular
matrix seemed to be the most important structural correlate of renal
function (r 0.524, P = 0.0001). Semiquantitative estimates of interstitial
extracellular matrix accumulation were less correlated with renal function
(r = 0.370, P = 0.01). The composition of the mesangial extracellular
matrix did not differ in patients and controls, with the exception of the
extent of laminin staining, which was significantly higher in patients. The
extent of fibronectin staining in patients correlated with the severity of
glomerular structural abnormalities. This study demonstrates that the
severity of renal insufficiency in a variety of renal diseases correlates with
the severity of glomerular pathology, when quantitative scoring is applied.
L-NAME inhibits the formation of peroxynitrite-modified proteins in
Thy-i nephritis. H. van Goor, H. Moshage, P. Heeringa, P.K. Cheung, and
J47, W Bakker, Departments of Pathology, Clinical Immunology, and Gastro-
enterology and Hepatology, University Hospital Groningen, Groningen, The
Netherlands. Peroxynitrite, a product of the reaction between nitric oxide
(NO) and superoxide (02) is capable of inducing a series of oxidative
protein modifications, including formation of nitrotyrosine. In the present
paper we studied the role of iNOS, eNOS, and peroxynitrite in Thy-i
nephritis, a mesangioproliferative rat model known to be associated with
superoxide (02). Thy-I nephritis was induced in female PVG/c rats by i.v.
injections with MoAb ER4 (anti-Thy-i). Groups of rats (N = 5) were
sacrificed at 4 hours, 24 hours, 3 days, 7 days, and 14 days. Additional
anti-Thy-i injected rats (N = 5) were treated with the NOS inhibitor
L-NAME (0.75 mg/mI drinking water) and sacrificed at 3 days. Proteinuria
was significantly elevated in Thy-i rats at 3 days and 7 days compared to
controls (P < 0.05). Proteinuria in L-NAME treated rats was significantly
higher than in Thy-i rats at 3 days (P < 0.01). Serum nitrite/nitrate levels
were significantly reduced in L-NAME treated rats compared to Thy-i
rats at 3 days (19.4 0.7 .rM vs. 41 1.7 ovi; P < 0.01). Urine
nitrite/nitrate levels were also significantly lower in L-NAME treated rats
than in Thy-i rats at 3 days (1368 201 nmol vs. 2852 258 nmol; P <
0.02). Glomerular staining for iNOS was absent at all time points except
for an occasional positive cell at the early time points. Glomerular
immunoreactivity for eNOS was focally present at 4 hours. Strong
glomerular mesangial staining was found at 24 hours, 3 days, and 7 days,
while staining was weak at i4 days. Glomerular nitrotyrosine immunore-
activity was absent at 4 hours, moderate at 24 hours, strong at 3 days,
moderate at 7 days, and absent at 14 days. Nitrotyrosine was predomi-
nantly found in the mesangial areas. In L-NAME treated Thy-i rats
staining reactivity for nitrotyrosine was significantly reduced compared to
non-treated Thy-i rats at the same time point. Double labeling experi-
ments confirmed that both eNOS and nitrotyrosine colocalized with the
injected Thy-i antibody in the glomerular mesangium. These data suggest
that in Thy-i nephritis: (1) eNOS, not iNOS, is associated with peroxyni-
trite formation; (2) L-NAME inhibits the formation of nitrotyrosine.
Role of nitric oxide in renal vascular resistance in SHR before and after
uninephrectomy. M. T. Yalniz, f.A. foles, Ti. Rabelink, and HA. Koomans,
Physiology, Ege University, Izmir, Turkey; and Nephrology, Utrecht, Nether-
lands. Renal vascular resistance (RVR; mm Hg/mi/mm) is increased in
SHR as compared to WKY. If this is due to deficiency of nitric oxide
(NO), the fall in RVR induced by uninephrectomy may also be reduced.
RVR, as well as the response to NOS inhibitor, N°-L-arginine (NLA: 10
gIkg/min infusion), was measured in intact (2K) SHR and WKY, or 1
week after uninephrectomy (1K). Total and Ca-independent renal NOS
activity (pmol/min/mg protein) was evaluated by arginine-citrulline con-
version in kidney homogenate. Twenty-four hour urine NO2 + NO1








































Ca-md. NOS act. 2.2 0.20 1.4 0.13 2.2 0.13 1.4 0.05"
Baseline data: "P < 0.05 vs. 2K; "P < 0.05 vs. WKY)
Uninephrectomy decreased UNXV and in vitro Ca-i. NOS activity in
WKY and SHR. Yet, SHR showed more renal dilation (hyperfiltration
and hyperperfusion) after uninephrectomy than WKY.
WKY-2K WKY-1K SHR-2K SHR-1K
MAP 116 8" 112 8" 173 6"" 180 3ha
GFR/K 1.10 0.10" 1.34 0.06"" 0.94 0.06" 1.44 0.06""
FF 42.5 2.9c 41.5 2.4' 52.5 2.2"" 54.0 3.3""
RVR/K 25.0 3.0' 20.8 1.9' 473 43ba 37.2 2.0""
NLA data hyper: "P < 0.05 vs. 2K; "P < 0.05 vs. WKY; c P < 0.01 vs.
baseline
Although NLA enhanced FF similarly in all groups, the increase in RVR
was greater in 2K and 1K SHR than the respective changes in WKY. Thus,
contrary to our assumption, there was no absolute deficiency of NOS
activity in the SHR kidney, and RVR fell markedly after uninephrectomy.
NO-mediated vasodilation in 2K and 1K SHR, although increased in
comparison to the response in WKY, cannot counteract the prevailing
vasoconstriction.
Spiral CT angiography and detection of renal artery stenosis. P..!. G. van
de Yen, R. Kaatee, if. Beutler, F.J.A. Beck, W.P. Th.M. Mali, and H.A.
Koomans, Department of Nephrologv and Hypertension and Radiolo,
University Hospital Utrecht, Utrecht, The Netherlands. To assess the accu-
racy of spiral computed tomographic angiography (SCTA) in the detec-
tion of renal artery stenosis, we compared this imaging technique to
arterial digital subtraction angiography (ADSA). Seventy-one consecutive
patients with suspected renovascular disease were evaluated subsequently
with SCTA and ADSA. SCTA data were reconstructed to obtain multi-
planar reformatted (MPR) and maximum intensity projection (MIP)
images. The stenoscs were graded according to a three-point scale: 1 =
0—49%, 2 = 50—99%, 3 = occlusion. Evaluation of the renal arteries on
SCTA was performed by two independent radiologists, reviewer A and B,
who were unaware of the results on ADSA. Thirty-six patients (51%) had
renal dysfunction (serum creatininc l30 jLmol/liter) at baseline. ADSA
showed 142 kidneys with 166 arteries. Eighty-one significant stenoses
(grade 2) and 15 occlusions (grade 3) were found in 55 patients. All
arteries, including the accessory arteries, were identified with SCTA by
both reviewers, Individual results of stenosis scoring were as following:
SCTA stenosis grade
ADSA stenosis
Grade 1 2 3
Reviewer A B A B A B
1(N=70) 68 65 2 5 — —
2(N=81) 5 2 76 79 — —
3(N=15) — — — — 15 15
Sensitivity and specificity for detection of stenosis (grade 2 and 3) were
95% and 97%, respectively, for reviewer A and 98% and 93% for B. The
kappa index for the interohscrver readings was 0.9. No patients had a
significant persistent rise of serum ereatinine (>10% baseline value) after
SCTA. In conclusion, SCTA is a sensitive imaging technique for detection
of renal artery stenosis. SCTA can be performed safely in patients with
pre-existing renal dysfunction.
Is the antiproteinuric response of inhibition of the renin-angiotensin
system (RAS) less effective during the night? H. Buter, M.H. Hemmelder,
P. van Paassen, G.J. Navis, D. de Zeeuw, and P.E. de Jong, Groningen
Institute Jbr Drugs Studies (GIDS), University Hospital Groningen, Gro-
ningen, The Netherlands. In patients with glomerular disease, proteinuria
usually has a circadian pattern with a maximum during the day. We
questioned whether antiproteinuric treatment by interference in the RAS
would reduce proteinuria as effectively during nighttime as during day-
time. Eight ambulant patients (Upr,,t 6.6 2.4 g/day, Cr 78 24 mI/mm)
were studied before and at the end of six weeks treatment with the ACE
inhibitor trandolapril (4 mg o.i.d, 8:00 AM). On study days urine was
collected over daytime (8.00—23.00) and over nighttime (23.00—8.00)
portions (data given as Uprot g/hr) and 24 hour blood pressure was
measured. In addition, six hospitalized patients (Uprot 10.2 3.6 g/day,
C, 42 4 mI/mm) were studied before and on the 8th day of treatment
with the renin inhibitor remikiren (600 mg o.i.d) during standardized
conditions and during a rhythm diet. Urine was collected every 4 hours
and 24 hour blood pressure was measured. Data are given from 14.00 till




















Remikiren 102 8" 96 II" 0.22 0.11" 0.19 0.11
Data are expressed as mean SD: "P < 0.05 vs. placebo; b P < 0.05 vs.
day Wilcoxon signed rank test
During placebo both proteinuria and blood pressure display a circadian
pattern. ACE- and renin-inhibition reduce both daytime and nighttime
blood pressure. ACE- and renin-inhibition reduce proteinuria during the
day. This antiproteinuric response was less effective during the night. This
difference in renal responsiveness between day and night may be due to
differences in RAS activation between day and night. Decreased nocturnal
antiproteinuric efficacy may contribute to rest-proteinuria during treat-
ment and may affect long-term renal outcome. Studies in a larger group of
patients are needed to further explore this phenomenon and to see
whether alternative dosage regimens can improve nocturnal antiprotein-
uric efficacy.
Renal effects of low- and high-dose atrial natriuretic peptide in patients
with sickle cell disease. J. C. ter IVlaaten, L. W. Statius van Eps, P.M. ter Wee,
iC. Roos, A.J.M. Donker, and ROB. Gans, Department of Medicine,
ICaR- VU, Research School University Hospital Vnje Universiteit, Amster-
dam, The Netherlands. The exact mechanisms of natriuresis induced by
atrial natriuretic peptide (ANP) are unclear. ANP may induce natriuresis
by increasing GFR and decreasing both proximal and distal sodium
reabsorption. It has been suggested that low-dose ANP increases the flow
through the vasa recta and, thus, the renal interstitial pressure leading to
increased sodium excretion. Patients with sickle cell disease are charac-
terized by loss of the vasa recta and loops of Henle of the juxtamedullaiy
nephrons. After 2 basal hourly clearance periods, we assessed the effects
of low- (0.3 pmol/kg/min) and high-dose (2 pg/mm) ANP, each during a 2
hour period, on renal hemodynamics and sodium handling in 8 patients
with sickle cell disease (renal concentrating capacity 435 51 mOsm/kg).
Time control experiments were performed in the same subjects. Clear-
ances of 1311-Hippuran, 125l-Iothalamate, sodium and lithium were used to
evaluate RPF, GFR, FF, and fractional proximal (FPR) and distal (FDR)
sodium reabsorption. During low-dose ANP infusion, changes in RPF,
GFR, FF, CN,, FPR, and FDR were not different from the time control
study. During high-dose ANP infusion, RPF was unaltered, whereas GFR
increased from 115 34 to 130 36 ml/min, and FF from 19.7 4.0 to
21.8 3.9% (both P < 0.01 vs. time control). CN increased from 1.53
1.16 to 6.22 4.32 mI/mm (P < 0.001 vs. time control). FPR decreased
from 74.8 10.4 to 68.1 12.1%, and FDR decreased from 94.1 2.9 to
84.3 6.5% (P = 0.01 and P < 0.001 vs. control, respectively).
Conclusions: High-dose ANP increases sodium excretion in patients with
sickle cell disease by an increase of the GFR and a decline in both FPR
and FDR. Low-dose ANP does not affect renal hemodynamics and sodium
excretion in these patients. It remains to he established whether low-dose
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ANP affects sodium excretion by increasing medullary blood flow in
normal individuals. Control experiments are warranted.
Renal effects of insulin in patients with sickle cell disease. J. C. ter
Maaten, L. W Statius van Eps, J.C. Roos, P.M. ter Wee, AiM. Donker, and
ROB. Gans, Department of Medicine, ICaR-VU, Research School Univer-
sity Hospital Vrije Universiteit, Amsterdam, The Netherlands. Insulin induces
renal sodium retention, but it is not clear where in the nephron insulin
exerts its action. In previous studies in healthy volunteers, we found that
insulin decreases sodium excretion beyond the proximal tubule, but we
could not discriminate between the loops of Henle and more distal tubular
Sites. Patients with sickle cell disease are characterized by loss of the vasa
recta and loops of Henle of the juxtamedullary nephrons. After 2 basal
hourly clearance periods, we assessed, using the euglycemic clamp tech-
nique, the effect of exogenous insulin (50 mU/kglhr) during a 4 hour
period on renal hemodynamics and sodium handling in 8 patients with
sickle cell disease (renal concentrating capacity 435 51 mOsml/kg).
Time control experiments were performed in the same subjects. Clear-
ances of 1311-Hippuran, 1251-lothalamate, sodium and lithium were used to
evaluate RPF, GFR, FF, and fractional proximal (FPR) and distal (FDR)
sodium reabsorption.
Time control Clamp experiment
Baseline 4th hour Baseline 4th hour
RPF mI/mm 607 205 621 203 633 217 694 242"
GFRmI/min 109±34 113±33 114±37 120±34a
FF % 18.2 4.4 18.6 3.7 18.5 4.4 17.7 3.2
CNa mI/mm L30 0.46 1.58 1.13 1.60 1197 1.29 0.70
FPR % 78.1 4.8 80.6 7.0 79.4 9.6 70.6 11.5
FDR % 94.1 2.2 92.5 3.3 92.6 4.2 96.0
P < 0.05, "P < 0.001 vs. baseline
cp < 0.05, Up < 0.001 vs. time control
Conclusions: Insulin exerts an antinatriuretic effect at a distal tubular site
with a concomitant decrease in FPR in patients with sickle cell disease. In
contrast to studies in healthy subjects, net sodium retention was absent.
We postulate that, apart from the insulin-induced sodium reabsorption at
a site beyond the long loops of Henle, additional sodium retention in the
long loops of Henle may exist in normal individuals.
Verapamil is not as effective as ACE inhibition in the reduction of
non-diabetic proteinuria. M.H. Hemmelder, D. de Zeeuw, and P.E. de Jong,
University Hospital Groningen, Groningen, The Netherlands. The antipro-
teinuric response within the class of calcium channel antagonists is
debated. Nifedipine shows little response, whereas verapamil has an
antiproteinuric capacity comparable to that of ACE inhibition, at least in
diabetic proteinuria. We studied the efficacy of verapamil SR (360 mg),
the ACE inhibitor trandolapril (4 mg), and a fixed combination verapamil
SR/trandolapril (180/2 mg) on proteinuria in 11 non-diabetic patients with
proteinuria >3.0 g/day and creatinine clearance >40 mI/mm in a double-
blind, placebo-controlled, and random cross-over fashion. Three patients
had an untreated DBP  95 mm Hg. During the study patients adhered to
a 50—100 mmol/day sodium restricted diet and had a stable protein intake.
At the end of each 6-week study period three consecutive 24-hour urine
collections were made as well as a 24-hour blood pressure recording and
measurement of GFR ('251-iothalamate) and ERPF (1311-hippuran). Data
are given in table. For reasons of visibility median values are depicted
without ranges.
Pla ACEi Pla CCB Pla Combination
Proteinuria g 6.2 37a 6.3 59a 6.3 3.2













FF 0.23 0.18' 0.21 0.22 0.22 ft20
a P < 0.05 vs. preceding Pla.
Although proteinuria was significantly reduced during all 3 treatments,
verapamil reduced proteinuria significantly less compared to trandolapril
and the combination [—12% (25/17) vs. —51% (59/23) and —41% (63/7),
respectivelyj. The 24-hour DBP did not change during verapamil, whereas
both trandolapril and combination showed a comparable reduction of
DBP in these generally normotensive patients. Verapamil showed no
significant effects on renal hemodynamics, whereas both trandolapril and
the combination treatment increased ERPF and decreased FF. No
relation could be observed between the changes in DBP, renal hemody-
namies and proteinuria. In contrast to previous studies in diabetic renal
disease, verapamil is not as effective as ACE inhibition in the reduction of
proteinuria in non-diabetic renal disease. In addition, a fixed combination
of verapamil and ACE inhibition has similar effects compared to single
trandolapril treatment.
Genetic control of susceptibility to glomerular damage in rats with
L-NAME-induced hypertension. R.P.E. Van Dokkum, H.J. Jacob, andA.P.
Provoost, Erasmus University, Rotterdam, The Netherlands, and Medical
College of Wisconsin, Milwaukee, Wisconsin, USA. Inbred male fawn-
hooded hypertensive (FHH) rats develop early systemic and glomerular
hypertension, leading to progressive proteinuria, glomerulosclerosis (GS),
and premature death. Using a backeross of F1(FHH X ACT) X FHH rats,
we identified a locus on rat chromosome 1 (named Rf-1), linked with renal
damage but not with systolic blood pressure (SBP), indicating that both
traits are under separate genetic control. We surmised that Rf-1 is a major
determinant of the susceptibility to develop hypertension-associated renal
damage. This was tested by studying the effects of L-NAME-induced
hypertension on albuminuria (UaV) and GS in ACT, FHH, and (FHH )<
ACI)F1 rats. L-NAME was given in a low dose (LD) of 75—100 or a high
dose (HD) of 175—250 mg/liter drinking fluid, from 7 weeks of age. Tail
cuff SBP was assessed weekly, UaV after 3, 7, and 11 weeks of treatment.
Incidence of GS was determined in kidneys obtained at the end of
follow-up or after premature death. All strains developed a dose-depen-
dent progressive increase in SBP. FHH rats developed severe UaV after
3 weeks of treatment, progressing with time. Only 3 rats (all on LD) out
of 23 treated FHH survived till the end of follow-up. Despite the presence
of severe hypertension ACT rats treated with HD showed only a moderate
increase in UaV at weeks 7 and 11, while Fl rats showed intermediate
responses. At week 7 there was a modest rise in UaV in HD treated Fl
rats, which had increased at week 11, when Fl rats on LD also showed a
significant increase in UaV. The incidence of GS showed similar differ-
ences between the strains. FHHs were severely affected, while ACIs
showed only a modest degree of GS, with Fis being intermediate.
Comparison of the relationship between UaV and SBP showed that ACTs
were largely protected from developing marked UaV up to a SBP level of
225 mm Hg, the Fis to about 180 mm Hg, while FHHs were not protected
at all. These data indicate that the susceptibility to develop glomerular
damage is indeed genetically determined. Being heterozygous for the
FHH derived Rf-1 gene reduces the severity of renal damage, but does not
provide the same degree of protection as observed in the ACT rat that does
not carry Rf-1.
In search of more biocompatible peritoneal dialysis fluids (PDF): An in
vitro study on potential new solutions. H.F.H. Brulez, P.M. ter Wee, S. V.
Snijders, AiM. Donker, and H.A. Verhnigh, Department of Nephrology,
Academic Hospital Vnje Universiteit, Amsterdam, and the Faculty of Clinical
Microbiology, Erasmus University, Rotterdam, The Netherlands. The impact
of potential PDF components on ATP content and viability of peripheral
blood polymorphonuclear (PMN) and mononuclear leukocytes (MN) was
tested. Lactate buffered (277 mOsm/liter) solutions of glycerol (GLY,
molecular weight 90), sebacic acid (SA, molecular weight 200), and a
polypeptide (PP, molecular weight 800), were studied at 5 different
concentrations at pH 74 and 5, and compared to 2.27% dextrose (D227).
Viability was tested by flow cytometric analysis of propidium iodide (PT)
uptake. All assays were performed after incubation of the cells for 30, 60
and 120 minutes in the PDF. Cells incubated in 0.1% gel Hanks' buffer
(GHBSS) served as control. At neutral pH, P1 uptake by PMN signifi-
cantly increased after 30 minutes in PDF with an osmolality >370
mOsm/liter (e.g. 56 17% increase in GLY 5%; P < 0.05). After 60 and
120 minutes P1 uptake was significantly affected by D227, GLY (0.5—5%)
and SA (0.1—3%). PP solutions did not affect P1 uptake. MN were less
affected by the test fluids than PMN. Compared to MN incubated in
GHBSS, PT uptake by MN was increased after 30 minute incubation in the
lactate buffer, in SA (1—3%) and in D227. At longer incubation periods, P1
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uptake was affected by most solutions in a dose-dependent way. If after
exposure to D227 and the acidified PDF MN were incubated for another
18 hours in a physiologic buffer at 3TC, an increase in P1 uptake was
observed. ATP content of PMN and MN was affected by high osmolality
and low pH. At neutral pH, ATP content of PMN and MN was positively
related to the PP concentration. MN exposed to the PDF at neutral pH for
not more than 30 minutes showed a normalization of their ATP content
after an 18 hour recovery period. After a 60 minute incubation period
ATP content remained stable, but if exposition had been 120 minutes,
ATP content would have decreased significantly. It is concluded that, even
after a 30 minute incubation period, leukocyte ATP content and viability
is affected by high osmolality (>370 mOsm/liter) and low pH of PDF. An
additional postosmotic and postacidic effect of PDF can be observed. The
addition of PP to PDF may improve biocompatibility.
Is intradialytic hypotension related to autonomic neuropathy?
B. Strayer, B.J. ten Voorde, P.M.J.M. de Vries, and P.M. ter Wee, Academic
Hospital Vrije Universiteit, Amsterdam, The Netherlands. Autonomic dys-
function is a common complication in uremic patients. In hemodialysis
patients, autonomic dysfunction is considered to participate in intradia-
lytic hypotension. We studied 29 patients on intermittent hemodialysis to
determine whether there is a direct relation between autonomic dysfunc-
tion and intradialytic hypotension. Autonomic function was tested by the
deep-breathing test (IE), the lying-to-standing test (HR), and the Valsalva
maneuver (VR) in 18 stable patients (group non-H) and 11 hypotension-
prone patients (group H), by means of computer-analyzed ORS detection.
Only 3 of the 29 patients were suffering from diabetes mellitus. The
prevalence of autonomic dysfunction (that is, either sympathetic or vagal
impairment according to the tests.) was 66% (19 out of 29 patients).
H SD Non-H SD Pvalue
Age years 48 17 51 17 NS
IE 10 6.8 11 7.3 NS
HR 1.16 0.10 1.15 0.11 NS
VR 1.27 0.15 1.39 0.33 NS
The results of the tests did not differ between the two groups: IE: the
maximum difference in heart rate (HR) during deep inspiration and deep
expiration (in beats per minute); HR: the ratio between the maximum and
the minimum HR after standing up; VR: the ratio between the maximum
HR after releasing pressure and the minimum HR during Valsalva
pressure. We conclude that the occurrence of intradialytic hypotension
cannot be explained by pre-existcnt autonomic dysfunction. In addition,
the prevalence of autonomic dysfunction in dialysis patients is very high
(66%).
Endothelium-dependent vasodilation of large arteries in peritoneal
dialysis patients. C. van Guldener, M.J.F.M. Janssen, J. Lambert, A.J.M.
Donker, and C.D.A. Stehouwer, Department of internal Medicine and
Nephrology, Academic Hospital and Institute for Cardiovascular Research,
Vrije Universiteit, Amsterdam, The Netherlands. The increased cardiovas-
cular morbidity and mortality in end-stage renal disease patients are not
completely accounted for by known atherosclerotic risk factors. Therefore,
arterial wall properties may be altered independently of these risk factors
by effects of chronic renal insufficiency, such as hyperhomocysteinemia.
An important arterial vessel wall property is endothelium-dependent
vasodilation. Endothelial dysfunction is a key factor in the development of
atherosclerosis. We assessed endothelium-dependent vasodilation of the
brachial artery in peritoneal dialysis (PD) patients and in healthy control(C) subjects by measuring the arterial diameter before and after reactive
hyperemia (RH), which elicits a shear stress-induced, endothelium-
dependent vasodilation. The endothelium-dependent (after RH) and the
endothelium-independent, glyceryl trinitrate (GTN)-induced vasodilation
were measured with a vessel wall movement detector system in 29 PD
patients and in 29 C subjects. The PD patients and the C subjects were
matched for gender and comparable for age, body mass index, systolic,
diastolic and mean arterial blood pressure, and smoking (Table). Vasodi-
lation was expressed as the percentage increase of the arterial diameter
after RH and after GTN. Given values are mean SEM. Vasodilation after
RH was markedly reduced in the PD group: 5.7 1.0 compared with
lt).4 1.3% in the C group (P < 0.01). After correction for baseline
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diameter, endothelium-dependent vasodilation remained reduced in the
PD group. Vasodilation after GTN was similar in the two groups.
PD(N=29) C(N=29)
Gender male/female 17/12 17/12
Age years





Smokers number 10 9
Systolic blood pressure mm Hg 136.2 3.7 131.9 2.7
Diastolic blood pressure mm Hg 77.6 2.5 78.4 2.0
Baseline brachial artery diameter mm 3.6 0.1 3.4 0.1
Vasodilation after RH % 5.7 1.0 10.4 1.Y'
Vasodilation after GTN % 9.6 1.1 10.5 1.0
ap <0.01
Conclusion: Chronic renal failure and/or chronic PD is associated with
impaired endothelium-dependent vasodilation, which may reflect an in-
creased susceptibility for the development of atherosclerosis and throm-
bosis. Studies on the effect of long-term homocysteine-lowering therapy
with folic acid on endothelium-dependent vasodilation are warranted.
The biological significance of the high levels of soluble TNF receptors
in patients on chronic hemodialysis. I. C. van Riemsdijk, C.J. Hesse,
R. Zietse, and W Weimar, Department of Internal Medicine I, University
Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands. TNF-a in its
active form is a trimeric macrophage-derived cytokine that forms part of
our basal immunological defense system. Soluble receptors (sTNF-R1,
sTNF-R2) appear to regulate the bioavailability of TNF-o in vivo, while
dysregulation of the TNF-a/sTNF-R, balance may lead to immunological
disturbances resulting in a state of immunosuppression. In patients on
renal replacement therapy the plasma levels of these receptors can be
markedly elevated and highly exceed the amount of TNF-cs. The biological
significance of this discrepancy is unknown. Therefore, in an attempt to
define the functional role of the TNF-a system in end-stage renal failure,
we measured both plasma levels of TNF-a (ELISA, CLB, Amsterdam,
Netherlands) and its circulating receptors sTNF-R1 and sTNF-R2
(ELISA, R&D Systems Europe, Abington, UK) in 9 patients on chronic
hemodialysis (age 32—83 years; 4 M/5 F). In all subjects TNF-a levels were
hardly detectable (4.1 2.8 pg/mI), while high amounts of soluble
receptors were found (sTNF-R1 12,415 1,830 pg/mI; sTNF-R2 22,897
4,178 pg/mI). These sTNF-R levels were not affected by polysulphone or
hemophane membrane hemodialysis procedures. To estimate the biolog-
ical significance of the sTNF-R levels, a standard solution of 200 pg/mI of
trimeric TNF-o was incubated with sTNF-R1, sTNF-R2, or patient
plasma. While the soluble receptors in a concentration of 1,250 pg/mI
reduced the amount of immunoreactive TNF-cs to 83 and 90%, respec-
tively, the recovery of TNF-a after incubation with patient plasma was
only 51.6% (34—70%). Apparently the high levels of soluble TNF recep-
tors present in plasma of patients on hemodialysis neutralize the action of
active TNF-a and may thereby contribute to a state of immunosuppression
leading to an increased susceptibility for infection and cancer.
Provocation of sympathoinhibitory presyncope by cold stress during
low cardiac output in healthy subjects and hemodialysis patients.
G. Ligtenberg, P.J. Blankestijn, P.L. Oey, G.H. Wieneke, A.C. van Huffelen,
and H.A. Koomans, Departments of Nephrology and Clinical Neurophysiol-
ogy, University Hospital Utrecht, Utrecht, The Netherlands. Acute hypoten-
sion during progressive hypovolemia has been attributed to sudden
inhibition of sympathetic activity. The same phenomenon probably under-
lies sudden hypotension during hemodialysis. It is unknown why this
paradoxical reaction occurs. We studied whether brief fluctuation of
sympathetic activity induced by cold stress evokes sympathoinhibition
during low cardiac output. Fourteen healthy subjects (age 25 4 years)
underwent lower body negative pressure (LBNP, 45 mm Hg, up to 60
mm). LBNP was accompanied by a fall in pulse pressure and in cardiac
output, tachycardia, and peripheral vasoconstriction. Six subjects tolerated
LBNP for 60 minutes. Eight developed hypotension at 17 6 minutes,
accompanied by relative bradycardia and withdrawal of vasoconstriction.
Muscle sympathetic nerve activity (MSNA) initially increased from 12
4 bursts/mm at rest to 53 19 bursts/mm, but suddenly decreased to 27 ±
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16 during the hypotensive phase. A cold pressor test (CPT) performed
before LBNP caused tachycardia and vasoconstriction and increased
MSNA. CPT during the seventh minute of LBNP again elicited a pressor
response, but was followed by acute hypotension in 10 subjects, associated
with vasorelaxation, relative bradycardia, and decrease of MSNA. We also
studied the effects of CPT before and in the final phase of hemodialysis in
eight stable patients (age 42 15 years). During dialysis, CPT provoked
acute hypotension in five, the ihemodynamic changes being identical as
found in the normal subjects. Conclusion: Brief cold stress, tolerated well
in normal circulatoiy conditions, can provoke sudden sympathoinhibition
during decreased cardiac output induced by LBNP or dialysis. Since this
sympathoinhibition follows the relaxation phase that automatically comes
after cold stress, we suggest that sympathetic relaxation can trigger full
sympathoinhibitory syncope during conditions of decreased cardiac Out-
put.
Simultaneous peritoneal dialysis catheter insertion and removal with-
out interruption of peritoneal dialysis. N. Posthuma, P..!. Borgstein,
Q. Eijsbouts, and P.M ter Wee, Department of Nephrology and Surgery,
Academic Hospital Vrije Universitei4 Amsterdam, The Netherlands. Simul-
taneous peritoneoscopic peritoneal dialysis (PD) catheter insertion and
removal was performed 36 times in 24 CCPD and 8 CAPD patients since
1992. Four procedures were performed for mechanical reasons, the
remaining for catheter-related infectious problems. Before the switch
procedure the dialysate leukocyte count had to be below 100/mm3 and
antibiotical coverage had to be appropriate. PD was restarted the day after
surgery: CCPD 1.7 2.3 days and CAPD 8.8 4.4 days, except one
patient who restarted the same day. After restarting, CCPD was used by
27 patients. They used low volume dwells and a diy abdomen during
daytime in the first week, then the regimen was gradually extended to
normal in the next week. Four CAPD patients discontinued PD (7—14
days) and chose hemodialysis treatment because they did not want to stay
in the hospital for CCPD treatment. Besides minor problems, such as
position-dependent outflow problems, we saw dialysate leakage in 2
patients. These patients were the only 2 that had intra-abdominal dialysate
during daytime (1 CCPD and 1 CAPD), and after two weeks interruption
PD was successfully restarted. In addition, 2 peritonitis episodes within the
first two weeks were seen. The first was not related to the procedure but
the second was (switched because of colonized catheter, another organism
in the old exit site: not covered by the prescribed antibiotics, leading to
catheter removal). One patient developed an abscess in the old tunnel (by
accident prophylactic antibiotics were not given). In the 4 procedure-
related complications there was a treatment protocol violation. Eventu-
ally, 35 out of 36 could continue PD. In conclusion, simultaneous PD
catheter insertion and removal is safe as long as the appropriate precau-
tions are taken.
